Concord Biotech Limited announced robust financial results for the second quarter and first half of FY27. The company reported a 25% year-on-year revenue growth for Q2 FY27, reaching ₹309.1 crore, and a 26% growth for H1 FY27, totaling ₹566.6 crore. This broad-based growth was driven by strong performance across all product categories and geographies, including significant expansion in the oncology business.
Concord Biotech Announces Strong Q2 and H1 FY27 Performance
Concord Biotech Limited has revealed a strong financial performance for the second quarter and the first half of the fiscal year 2027. The company reported a notable 25% year-on-year increase in revenues for Q2 FY27, amounting to ₹309.1 crore, compared to ₹247.1 crore in the corresponding period of FY26. This momentum carried into the first half of the year, with revenues growing by 26% to ₹566.6 crore from ₹451.1 crore in the same period last year.
Broad-Based Growth Across Segments
The company highlighted that the growth was particularly encouraging due to its broad-based nature, spanning every product category and geography. Key segments such as immunosuppressants, anti-infectives, antifungal, and oncology all demonstrated growth. The anti-infective, antifungal, and oncology segments showed faster percentage growth due to increased market penetration of recently commercialized products. The oncology business, in particular, nearly doubled compared to the prior year’s corresponding period.
API and Formulation Performance
API revenue saw a robust 30% year-on-year growth in the quarter, reaching ₹250.1 crore, while formulation revenue grew by 6% to ₹58.9 crore. The domestic formulation business delivered a strong 29% growth in Q2 FY27. While overall formulation revenue growth was modest, it was attributed to shifts in procurement strategies in emerging markets and the transition of business to its US subsidiary.
Regulatory Approvals and New Launches
In terms of highlights for H1 FY27, Concord Biotech received ANDA approvals for Tofacitinib and Mycophenolate Mofetil Oral Suspension, strengthening its formulation portfolio. Additionally, a Drug Master File for Fidaxomicin was filed in the US, enhancing API opportunities. The company also successfully completed a USFDA inspection of its Unit-II formulation facility and received ANVISA approval for its Unit-III facility. The launch of its dermatology division, Inspira, marks an expansion into science-led skin health solutions.
Financial Highlights and Outlook
EBITDA for Q2 FY27 stood at ₹104.4 crore, an 18% increase year-on-year. For H1 FY27, EBITDA grew by 25% to ₹187 crore, with EBITDA margins remaining stable at 33%. Profit After Tax (PAT) for Q2 FY27 was ₹69.6 crore, a 10.3% growth, and for H1 FY27, PAT increased by 19% to ₹127.3 crore. The company continues to maintain a zero-debt balance sheet with cash and cash equivalents of approximately ₹445 crore as of September 30, 2026.
Strategic Focus
Concord Biotech remains focused on leveraging its expertise in fermentation technology and its robust API portfolio. The company is actively exploring CDMO opportunities and building its presence in the US formulation market through Stellon. Strategic priorities include deepening customer relationships, expanding market presence, capitalizing on emerging opportunities, and investing in core capabilities to drive sustainable long-term growth.
Source: BSE
